Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 367

1.

Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Reinert T, Gonçalves R, Ellis MJ.

Curr Treat Options Oncol. 2018 Apr 16;19(5):23. doi: 10.1007/s11864-018-0538-9. Review.

PMID:
29663173
2.

Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer.

Nair A, Chung HC, Sun T, Tyagi S, Dobrolecki LE, Dominguez-Vidana R, Kurley SJ, Orellana M, Renwick A, Henke DM, Katsonis P, Schmitt E, Chan DW, Li H, Mao S, Petrovic I, Creighton CJ, Gutierrez C, Dubrulle J, Stossi F, Tyner JW, Lichtarge O, Lin CY, Zhang B, Scott KL, Hilsenbeck SG, Sun J, Yu X, Osborne CK, Schiff R, Christensen JG, Shields DJ, Rimawi MF, Ellis MJ, Shaw CA, Lewis MT, Westbrook TF.

Nat Med. 2018 May;24(4):505-511. doi: 10.1038/nm.4507. Epub 2018 Mar 26.

PMID:
29578538
3.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.

Robertson JFR, Cheung KL, Noguchi S, Shao Z, Degboe A, Lichfield J, Thirlwell J, Fazal M, Ellis MJ.

Eur J Cancer. 2018 May;94:206-215. doi: 10.1016/j.ejca.2018.02.026. Epub 2018 Mar 22.

4.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Mar 15. doi: 10.1093/jnci/djy017. [Epub ahead of print]

PMID:
29554282
5.

Mass spectrometry-based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibitors in triple negative breast cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 Feb 22. pii: canres.1990.2017. doi: 10.1158/0008-5472.CAN-17-1990. [Epub ahead of print]

PMID:
29472518
6.

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.

Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G.

Oncotarget. 2018 Jan 8;9(6):6924-6937. doi: 10.18632/oncotarget.24023. eCollection 2018 Jan 23.

7.

Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON).

Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z.

Breast Cancer. 2018 May;25(3):356-364. doi: 10.1007/s12282-018-0838-8. Epub 2018 Feb 15.

PMID:
29450827
8.

Patient-Specific Alterations in CO2 Cerebrovascular Responsiveness in Acute and Sub-Acute Sports-Related Concussion.

Mutch WAC, Ellis MJ, Ryner LN, McDonald PJ, Morissette MP, Pries P, Essig M, Mikulis DJ, Duffin J, Fisher JA.

Front Neurol. 2018 Jan 24;9:23. doi: 10.3389/fneur.2018.00023. eCollection 2018.

9.

Management and Return to Play Considerations in an Elite Hockey Player with Temporal Lobe Epilepsy.

Ellis MJ, Ritchie L, Essig M, Ng M, Tamayo A, Serletis D.

Curr Sports Med Rep. 2018 Jan;17(1):10-12. doi: 10.1249/JSR.0000000000000439. No abstract available.

PMID:
29315101
10.

Management of an Adolescent Athlete with Sports-Related Concussion and Intraparenchymal Hemorrhage.

Ellis MJ, Barnes J, Cordingley DM, Bunge M, McDonald PJ, Ritchie L.

Curr Sports Med Rep. 2018 Jan;17(1):7-9. doi: 10.1249/JSR.0000000000000438. No abstract available.

PMID:
29315100
11.

Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.

Pillai SG, Li S, Siddappa CM, Ellis MJ, Watson MA, Aft R.

Breast Cancer Res. 2018 Jan 2;20(1):2. doi: 10.1186/s13058-017-0927-1.

12.

TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.

Byrd TT, Fousek K, Pignata A, Szot C, Samaha H, Seaman S, Dobrolecki L, Salsman VS, Oo HZ, Bielamowicz K, Landi D, Rainusso N, Hicks J, Powell S, Baker ML, Wels WS, Koch J, Sorensen PH, Deneen B, Ellis MJ, Lewis MT, Hegde M, Fletcher BS, St Croix B, Ahmed N.

Cancer Res. 2018 Jan 15;78(2):489-500. doi: 10.1158/0008-5472.CAN-16-1911. Epub 2017 Nov 28.

PMID:
29183891
13.

Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.

Zhou JY, Chen L, Zhang B, Tian Y, Liu T, Thomas SN, Chen L, Schnaubelt M, Boja E, Hiltke T, Kinsinger CR, Rodriguez H, Davies SR, Li S, Snider JE, Erdmann-Gilmore P, Tabb DL, Townsend RR, Ellis MJ, Rodland KD, Smith RD, Carr SA, Zhang Z, Chan DW, Zhang H.

J Proteome Res. 2017 Dec 1;16(12):4523-4530. doi: 10.1021/acs.jproteome.7b00362. Epub 2017 Nov 16.

14.

Silent but deadly: IS200 promotes pathogenicity in Salmonella Typhimurium.

Ellis MJ, Carfrae LA, Macnair CR, Trussler RS, Brown ED, Haniford DB.

RNA Biol. 2018 Feb 1;15(2):176-181. doi: 10.1080/15476286.2017.1403001. Epub 2017 Dec 8.

PMID:
29120256
15.

Reply.

Ellis MJ, Ritchie L, McDonald P, Russell K.

Clin J Sport Med. 2017 Sep 28. doi: 10.1097/JSM.0000000000000490. [Epub ahead of print] No abstract available.

PMID:
28976404
16.

Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?

Haricharan S, Ellis MJ.

Oncoscience. 2017 Sep 21;4(7-8):77-78. doi: 10.18632/oncoscience.363. eCollection 2017 Jul. No abstract available.

17.

Chemical genomics reveals mechanistic hypotheses for uncharacterized bioactive molecules in bacteria.

French S, Ellis MJ, Coutts BE, Brown ED.

Curr Opin Microbiol. 2017 Oct;39:42-47. doi: 10.1016/j.mib.2017.09.005. Epub 2017 Sep 26. Review.

PMID:
28957731
18.

Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.

Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA Jr, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K.

Clin Cancer Res. 2017 Dec 1;23(23):7288-7300. doi: 10.1158/1078-0432.CCR-17-1544. Epub 2017 Sep 25.

19.

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer.

Ma CX, Suman V, Goetz MP, Northfelt D, Burkard ME, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tevaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, Hieken T, Barnell EK, Skidmore ZL, Feng YY, Krysiak K, Hoog J, Guo Z, Nehring L, Wisinski KB, Mardis E, Hagemann IS, Vij K, Sanati S, Al-Kateb H, Griffith OL, Griffith M, Doyle L, Erlichman C, Ellis MJ.

Clin Cancer Res. 2017 Nov 15;23(22):6823-6832. doi: 10.1158/1078-0432.CCR-17-1260. Epub 2017 Sep 5.

PMID:
28874413
20.

Zirconium amine tris(phenolate): A more effective initiator for biomedical lactide.

Jones MD, Wu X, Chaudhuri J, Davidson MG, Ellis MJ.

Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:69-74. doi: 10.1016/j.msec.2017.03.242. Epub 2017 Mar 29.

PMID:
28866217
21.

Graded Aerobic Treadmill Testing in Adolescent Traumatic Brain Injury Patients.

Cordingley DM, Girardin R, Morissette MP, Reimer K, Leiter J, Russell K, Ellis MJ.

Can J Neurol Sci. 2017 Nov;44(6):684-691. doi: 10.1017/cjn.2017.209. Epub 2017 Aug 29.

PMID:
28849757
22.

CDK4/6 inhibition triggers anti-tumour immunity.

Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, Winer EP, Roberts TM, Kim HJ, McAllister SS, Zhao JJ.

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

23.

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.

Haricharan S, Punturi N, Singh P, Holloway KR, Anurag M, Schmelz J, Schmidt C, Lei JT, Suman V, Hunt K, Olson JA Jr, Hoog J, Li S, Huang S, Edwards DP, Kavuri SM, Bainbridge MN, Ma CX, Ellis MJ.

Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.

PMID:
28801307
24.

Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner.

Wang X, Mooradian AD, Erdmann-Gilmore P, Zhang Q, Viner R, Davies SR, Huang KL, Bomgarden R, Van Tine BA, Shao J, Ding L, Li S, Ellis MJ, Rogers JC, Townsend RR, Fenyö D, Held JM.

Sci Signal. 2017 Aug 8;10(491). pii: eaam8065. doi: 10.1126/scisignal.aam8065.

25.

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.

Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC.

Clin Cancer Res. 2017 Oct 1;23(19):5687-5695. doi: 10.1158/1078-0432.CCR-17-0900. Epub 2017 Jul 5.

PMID:
28679771
26.

Lessons in precision oncology from neoadjuvant endocrine therapy trials in ER+ breast cancer.

Ellis MJ.

Breast. 2017 Aug;34 Suppl 1:S104-S107. doi: 10.1016/j.breast.2017.06.039. Epub 2017 Jun 30.

27.

Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity.

Zhang X, Kim S, Hundal J, Herndon JM, Li S, Petti AA, Soysal SD, Li L, McLellan MD, Hoog J, Primeau T, Myers N, Vickery TL, Sturmoski M, Hagemann IS, Miller CA, Ellis MJ, Mardis ER, Hansen T, Fleming TP, Goedegebuure SP, Gillanders WE.

Cancer Immunol Res. 2017 Jul;5(7):516-523. doi: 10.1158/2326-6066.CIR-16-0264. Epub 2017 Jun 15.

PMID:
28619968
28.

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer.

Goncalves R, DeSchryver K, Ma C, Tao Y, Hoog J, Cheang M, Crouch E, Dahiya N, Sanati S, Barnes M, Sarian LOZ, Olson J, Allred DC, Ellis MJ.

Breast Cancer Res Treat. 2017 Sep;165(2):355-364. doi: 10.1007/s10549-017-4329-y. Epub 2017 Jun 13.

29.

Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer.

Goncalves R, Reinert T, Ellis MJ.

J Clin Oncol. 2017 Aug 10;35(23):2718-2719. doi: 10.1200/JCO.2017.73.0424. Epub 2017 Jun 5. No abstract available.

PMID:
28581884
30.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM.

Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2.

PMID:
28464211
31.

Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.

Lesurf R, Griffith OL, Griffith M, Hundal J, Trani L, Watson MA, Aft R, Ellis MJ, Ota D, Suman VJ, Meric-Bernstam F, Leitch AM, Boughey JC, Unzeitig G, Buzdar AU, Hunt KK, Mardis ER.

Ann Oncol. 2017 May 1;28(5):1070-1077. doi: 10.1093/annonc/mdx048.

PMID:
28453704
32.

Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Townsend RR, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Apr 25;8:15479. doi: 10.1038/ncomms15479. No abstract available.

33.

Breast Cancer Patient-Derived Xenografts: Pros, Cons, and Next Steps.

Shafaee MN, Ellis MJ.

J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw307. No abstract available.

PMID:
28376181
34.

Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.

Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, Wyczalkowski MA, Erdmann-Gilmore P, Snider JE, Hoog J, Singh P, Niu B, Guo Z, Sun SQ, Sanati S, Kawaler E, Wang X, Scott A, Ye K, McLellan MD, Wendl MC, Malovannaya A, Held JM, Gillette MA, Fenyö D, Kinsinger CR, Mesri M, Rodriguez H, Davies SR, Perou CM, Ma C, Reid Townsend R, Chen X, Carr SA, Ellis MJ, Ding L.

Nat Commun. 2017 Mar 28;8:14864. doi: 10.1038/ncomms14864.

35.

A transposon-derived small RNA regulates gene expression in Salmonella Typhimurium.

Ellis MJ, Trussler RS, Charles O, Haniford DB.

Nucleic Acids Res. 2017 May 19;45(9):5470-5486. doi: 10.1093/nar/gkx094.

36.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

37.

Community Health Consequences of a Second-Impact Syndrome Death Following Concussion.

Scramstad C, Ellis MJ, Del Bigio MR.

Can J Neurol Sci. 2017 Mar;44(2):207-208. doi: 10.1017/cjn.2016.325. No abstract available.

PMID:
28231863
38.

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer.

Bai L, Zhou B, Yang CY, Ji J, McEachern D, Przybranowski S, Jiang H, Hu J, Xu F, Zhao Y, Liu L, Fernandez-Salas E, Xu J, Dou Y, Wen B, Sun D, Meagher J, Stuckey J, Hayes DF, Li S, Ellis MJ, Wang S.

Cancer Res. 2017 May 1;77(9):2476-2487. doi: 10.1158/0008-5472.CAN-16-2622. Epub 2017 Feb 16.

PMID:
28209615
39.

Longitudinal Assessment of Health-Related Quality of Life following Adolescent Sports-Related Concussion.

Russell K, Selci E, Chu S, Fineblit S, Ritchie L, Ellis MJ.

J Neurotrauma. 2017 Jul 1;34(13):2147-2153. doi: 10.1089/neu.2016.4704. Epub 2017 Mar 1.

PMID:
28077006
40.

Legislation for Youth Sport Concussion in Canada: Review, Conceptual Framework, and Recommendations.

Russell K, Ellis MJ, Bauman S, Tator CH.

Can J Neurol Sci. 2017 May;44(3):225-234. doi: 10.1017/cjn.2016.423. Epub 2017 Jan 10. Review.

PMID:
28069082
41.

Migraine with Aura or Sports-Related Concussion: Case Report, Pathophysiology, and Multidisciplinary Approach to Management.

Ellis MJ, Cordingley D, Girardin R, Ritchie L, Johnston J.

Curr Sports Med Rep. 2017 Jan/Feb;16(1):14-18. doi: 10.1249/JSR.0000000000000323.

PMID:
28067735
42.

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA Jr, Allred DC, Hunt K.

J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.

43.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

44.

An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.

Luo J, Liu S, Leung S, Gru AA, Tao Y, Hoog J, Ho J, Davies SR, Allred DC, Salavaggione AL, Snider J, Mardis ER, Nielsen TO, Ellis MJ.

J Mol Diagn. 2017 Jan;19(1):147-161. doi: 10.1016/j.jmoldx.2016.09.007.

45.

Reply: Can Dead Space Ventilation Really Be Measured without PaCO2?

Kee K, Stuart-Andrews C, Ellis MJ, Wrobel JP, Nilsen K, Thompson BR, Naughton MT.

Am J Respir Crit Care Med. 2016 Dec 15;194(12):1556-1557. No abstract available.

PMID:
27976939
46.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ.

Lancet. 2016 Dec 17;388(10063):2997-3005. doi: 10.1016/S0140-6736(16)32389-3. Epub 2016 Nov 29.

PMID:
27908454
47.

Epigenetic activation of the prostaglandin receptor EP4 promotes resistance to endocrine therapy for breast cancer.

Hiken JF, McDonald JI, Decker KF, Sanchez C, Hoog J, VanderKraats ND, Jung KL, Akinhanmi M, Rois LE, Ellis MJ, Edwards JR.

Oncogene. 2017 Apr 20;36(16):2319-2327. doi: 10.1038/onc.2016.397. Epub 2016 Nov 21.

48.

Proteome Profiling Outperforms Transcriptome Profiling for Coexpression Based Gene Function Prediction.

Wang J, Ma Z, Carr SA, Mertins P, Zhang H, Zhang Z, Chan DW, Ellis MJ, Townsend RR, Smith RD, McDermott JE, Chen X, Paulovich AG, Boja ES, Mesri M, Kinsinger CR, Rodriguez H, Rodland KD, Liebler DC, Zhang B.

Mol Cell Proteomics. 2017 Jan;16(1):121-134. doi: 10.1074/mcp.M116.060301. Epub 2016 Nov 11.

49.

Multidisciplinary Management of Pediatric Sports-Related Concussion.

Ellis MJ, Ritchie LJ, McDonald PJ, Cordingley D, Reimer K, Nijjar S, Koltek M, Hosain S, Johnston J, Mansouri B, Sawyer S, Silver N, Girardin R, Larkins S, Vis S, Selci E, Davidson M, Gregoire S, Sam A, Black B, Bunge M, Essig M, MacDonald P, Leiter J, Russell K.

Can J Neurol Sci. 2017 Jan;44(1):24-34. doi: 10.1017/cjn.2016.312. Epub 2016 Oct 24.

PMID:
27772532
50.

Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.

Lu J, McEachern D, Li S, Ellis MJ, Wang S.

Mol Cancer Ther. 2016 Dec;15(12):2887-2893. Epub 2016 Oct 7.

Supplemental Content

Loading ...
Support Center